CoChat
Cited by 191

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

Open access
Li, Jing, Wang, Weichao, Zhang, Yajia, Cieślik, Marcin, Guo, Jipeng, Tan, Mengyao, Green, Michael D., Wang, Weimin, Lin, Heng, Li, Wei, Wei, Shuang, Zhou, Jiajia, Li, Gaopeng, Jing, Xiaojun, Vatan, Linda, Zhao, Lili, Bitler, Benjamin, Zhang, Rugang, Cho, Kathleen R., Dou, Yali, Kryczek, Ilona, Chan, Timothy A., Huntsman, David, Chinnaiyan, Arul M., Zou, Weiping · 2020 · Journal of Clinical Investigation

Abstract

Myc amplification may transcriptionally regulate immune inhibition-associated molecules such as CD47 and PD-L1 in a mouse model of T cell acute lymphoblastic leukemia (12).In addition, Kras G12D can cause an increase in expression of the inflammatory cytokine GM-CSF in a mouse model of pancreatic neoplasia (13).Loss of P53 function activates the JAK2-STAT3 signaling pathway and promotes pancreatic tumor growth (14), and mutant P53 prolongs NF-kB activation and increases colorectal tumor incidence in a mouse model (15).These studies reveal a general mechanistic connection between cancer driver mutation-related inflammation and cancer progression in different model systems.However, the link among cancer driver gene mutations, T cell immunity, and immunotherapy response has not been established in patients with cancer.Thus, we have attempted to explore whether cancer genetic driver mutation(s) are capable of directly driving cancer immune phenotype, contributing to IFN signature and T cell immunity, and affecting immunotherapy response in models and in patients with cancer.Given that the most recurrent cancer driver genetic mutations, including MYC, APC, TP53, and KRAS, have been examined, in this work we focused our studies on the cancer driver epigenetic mutations such as ARID1A mutations (16)(17)(18)(19).ARID1A belongs to the SWI/SNF complex and is a core member of the ATP-dependent polymorphic BRG/BRM-associated factor (BAF) chromatin remodeling unit.SWI/SNF complex mutations Whether mutations in cancer driver genes directly affect cancer immune phenotype and T cell immunity remains a standing question.ARID1A is a core member of the polymorphic BRG/BRM-associated factor chromatin remodeling complex.ARID1A mutations occur in human cancers and drive cancer development.Here, we studied the molecular, cellular, and clinical impact of ARID1A aberrations on cancer immunity.We demonstrated that ARID1A aberrations resulted in limited chromatin accessibility to IFN-responsive genes, impaired IFN gene expression, anemic T cell tumor infiltration, poor tumor immunity, and shortened host survival in many human cancer histologies and in murine cancer models.Impaired IFN signaling was associated with poor immunotherapy response.Mechanistically, ARID1A interacted with EZH2 via its carboxyl terminal and antagonized EZH2-mediated IFN responsiveness.Thus, the interaction between ARID1A and EZH2 defines cancer IFN responsiveness and immune evasion.Our work indicates that cancer epigenetic driver mutations can shape cancer immune phenotype and immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci134402

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

Metadata

Authors
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., Wei, S., Zhou, J., Li, G., Jing, X., Vatan, L., Zhao, L., Bitler, B., Zhang, R., Cho, K. R., Dou, Y., Kryczek, I., Chan, T. A., Huntsman, D., Chinnaiyan, A. M., & Zou, W.
Venue
Journal of Clinical Investigation
Published
2020-04-20
Volume
130
Issue
5
Pages
2712-2726
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3004964052
Cited by
191
References
30
FWCI
7.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.